MediWound Ltd. MDWD 深 滬
已收盤 02-06 16:00:00 美东时间
17.79
+0.570
+3.31%
華盛通- 最 高17.90
- 今 開17.36
- 成交量 10.09万股
- 最 低 17.36
- 昨 收 17.22
- 總市值 2.28亿
- 52周最高 22.505
- 市盈率 靜 --
- 換手率 0.79%
- 52周最低 14.14
- 委 比 0.50%
- 總股本 1283.52万
- 歷史最高 135.17
- 量 比 0.95
- 振 幅 3.14%
- 歷史最低 7.10
- 每 手 1
- 風險率 1.40%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Vericel Announces Preliminary 2025 Financial Results and Business Updates
Vericel Corporation reported preliminary 2025 financial results, including total revenue of $276 million, with MACI revenue at $239.5 million and Burn Care at $36.5 million. Gross margin is expected to be 74%, and adjusted EBITDA margin 26%, with GAAP Net Income profitable for the second year. The company ended 2025 with $200 million in cash and no debt. Business highlights include record MACI implants, 20% MACI revenue growth for the third conse...
01-13 14:00
Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026
Vericel Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 2:15 p.m. ET. A webcast of the presentation will be available on the company's Investor Relations website. Vericel, a leader in advanced therapies for sports medicine and severe burn care, markets three products in the U.S., including MACI® and Epicel®, and holds rights to NexoBrid®.
01-06 13:30
MediWound Announces Peer-Reviewed Publication Of New Prospective Clinical Data Showing NexoBrid Substantially Reduces Embedded Particles Associated With Traumatic Tattoos Following Abrasion And Blast Injuries
MediWound Reports New Clinical Data Demonstrating NexoBrid®'s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast InjuriesProspective clinical data show NexoBrid® removes embedded particles
2025-12-10 20:13
MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
<p align="justify">MediWound Ltd. announced new clinical data showing that its product NexoBrid<sup>®</sup> effectively reduces embedded particles causing traumatic tattoos after abrasion and blast injuries. In a study published in the <i>Journal of Burn Care & Research</i>, 15 patients were treated with NexoBrid, resulting in a 92.5% reduction in pigmented wound surface. This innovative enzymatic therapy may offer a more precise and less inv...
2025-12-10 12:00
美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元
2025-11-24 11:23
HC Wainwright & Co. Maintains Buy on MediWound, Raises Price Target to $36
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains MediWound (NASDAQ:MDWD) with a Buy and raises the price target from $31 to $36.
2025-11-21 19:16
MediWound’s Q3 2025: Growth and Strategic Advances
Mediwound ( ($MDWD) ) has released its Q3 earnings. Here is a breakdown of the ...
2025-11-21 11:58
MediWound Q3 EPS $(0.24) Beats $(0.81) Estimate, Sales $5.429M Miss $6.646M Estimate
MediWound (NASDAQ:MDWD) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.81) by 70.44 percent. This is a 75.51 percent increase over losses of $(0.98) per share from the
2025-11-20 20:02
Earnings Scheduled For November 20, 2025
Companies Reporting Before The Bell • Atkore (NYSE:ATKR) is likely to report qu...
2025-11-20 19:11
